Novartis and Relation's target discovery deal falls under Novartis’ wider ploy to strengthen its immunology portfolio.

Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...

Pfizer is set to cut several jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg.

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006 from Lynk Pharmaceuticals.

China’s NMPA has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis ...

The UK's 14.5% drug rebate reduction may help to quell souring pharma sentiments, which stem from the nation's low spending on innovative drugs.

We explore the challenges and opportunities of eco-design in parenteral packaging, from alternative feedstocks and carbon ...

Golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as a monotherapy and ...

Formycon and Zydus Lifesciences have entered into an exclusive licensing and supply agreement for FYB206 in the US and Canada ...

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American ...

Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.

Biogen has received an NOC from Health Canada for Zurzuvae, a NAS, as a treatment for moderate or severe PPD in women.